Economic evaluation of ACE inhibitor treatment of nephropathy in patients with insulin-dependent diabetes mellitus in Italy

PharmacoEconomics

Volumn 12, Issue 1, 1997, Pages 67-75

  Garattini, Livio ^a,b   Brunetti, Massimo ^a   Salvioni, Franco ^a   Barosi, Mattia ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b CESAV   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GUANABENZ; HYDRALAZINE; LABETALOL; METHYLDOPA; MINOXIDIL; PLACEBO; PRAZOSIN; TERAZOSIN;

ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETIC NEPHROPATHY; DIALYSIS; DRUG COST; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH SERVICE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; ITALY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; NATIONAL HEALTH SERVICE; PRIORITY JOURNAL; PROTEINURIA;

EID: 0030762402     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199712010-00007     Document Type: Article

References (38)

1. Stephenson J, Fuller JB, the Eurodiab IDDM Complications Study Group. Microvascular and acute complications in IDDM patients: the Eurodiab IDDM Complications Study. Diabetologia 1994; 37: 278-85
2. Wang PH, Law J, Chalmus TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993; 341: 1306-9
3. Reichard P, Nilsson BY, Rosenqvist U. The effect of long term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993; 329: 304-9
4. Christlieb AR, Warram JH, Krolewski AS, et al. Hypertension: the major risk factor in juvenile onset insulin-dependent diabetes. Diabetes 1981; 30 Suppl. 2: 90-6
5. Mathiesen ER, Ronn B, Jensen T, et al. Relationship between blood pressure and urinary albumin excretion in development of microalbuminuria. Diabetes 1990; 39: 245-9
6. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86
7. Parving HH, Hommel E. Prognosis in diabetic nephropathy. BMJ 1989; 299: 230-3
8. Parving HH, Andersen AR, Smidt UM, et al. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. BMJ 1987; 294: 1143-7
9. Björck S, Mulec H, Johnsen SA, et al. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992; 304: 339-43
10. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62
11. Miles AN, Friedman EA. Dialytic therapy for diabetic patients with terminal renal failure. Curr Opin Nephrol Hypertens 1993; 2: 868-75
12. Catalano C, Postorino M, Kelly PJ, et al. Diabetes mellitus and renal replacement therapy in Italy: prevalence, main characteristics and complications. Nephrol Dial Transplant 1990; 5: 788-96
13. La Greca G, Catalano C, Dell'Aquila R, et al. Epidemiology of kidney failure in diabetic patients in Italy. Acta Diabetol 1992; 29: 167-72
14. Garattini L, Grilli R, Scopelliti D, et al. A proposal for Italian guidelines in pharmacoeconomics. Pharmacoeconomics 1995; 7 (1): 1-6
15. Drummond MF. Principles of economic appraisal in health care. Oxford: Oxford University Press, 1980
16. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1987
17. Johannesson M, Jonsson B, Karlsson G. Outcome measurement in economic evaluation. Health Econ 1996; 5: 279-96
18. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977; 31: 716-21
19. Keeler EB, Kretin S. Discounting of life-savings and other non-monetary effects. Manage Sci 1983; 29 (3): 300-6
20. Informatore Farmaceutico. I medicinali. Milan: Organizzazione Editoriale Medico Farmaceutica, 1993
21. Ruggenenti P, Remuzzi G. Diagnosis of renal involvement in non insulin dependent diabetes mellitus. Curr Opin Nephrol Hypertens 1997; 6 (2): 141-5
22. Decreto Ministero della Sanità n. 80 del 7/11/91. Revisione del nomenclatore tariffario delle prestazioni specialistiche ambulatoriali. Supplemento ordinario alla Gazzetta Ufficiale della Repubblica Italiana n. 286 del 6/12/91. Roma: Istituto Poligrafico e Zecca dello Stato, 1991
23. Brunetti M, Barosi M, Salvioni F, et al. Analisi dei costi diretti della dialisi in un campione di presidi ospedalieri. G Ital Nefrol 1996; 13 (3): 187-94
24. Marcelli D, Spotti D, Conte F, et al. Prognosis of diabetic patients on dialysis: analysis of Lombardy Registry Data. Nephrol Dial Transplant 1995; 10: 1895-900
25. Vesconi D, Zanelli E, Garattini L. Analisi dei costi per divisione su un campione di nove presidi ospedalieri. Agenzia Sanitaria Italiana (ASI) 1996; 10: 33-7
26. Briggs A, Schulper M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ 1994; 3: 95-104
27. Borch-Johnsen K, Wenzel H, Viberti GC, et al. Is screening and intervention for microalbuminuria worthwhile in patients with insulin-dependent diabetes? BMJ 1993 306: 1722-5
28. Siegel JE, Krolewski AS, Warram JH, et al. Cost-effectiveness of screening and early treatment of nephropathy in patients with insulin-dependent diabetes mellitus. J Am Soc Nephrol 1992; 3: S111-9
29. Rodby RA, Lewis EJ, Firth LM. An economic analysis of ET in the treatment of diabetic nephropathy. Diabetes Care 1996; 19 (10): 1051-1061
30. Rodby RA, Lewis EJ. ACE inhibition in diabetic patients: economic implications. Pharmacoeconomics 1996; 10 (4): 315-20
31. Remuzzi G, Ruggenenti P. Slowing the progression of diabetic nephropathy. N Engl J Med 1993; 329 (20): 1496-7
32. Lloyd CE, Fulier JH, Stephenson J, et al. A comparison of renal disease across two continents: the epidemiology of diabetes complications study and the EURODIAB IDDM complications study. Diabetes Care 1996; 19 (3): 219-25
33. Evans RW, Manninen DL, Garrison LP, et al. The quality of life of patients with end-stage renal disease. N Engl J Med 1985; 312 (9): 553-9
34. Deniston OL, Carpentier-Alting P, Kneisley J, et al. Assessment of quality of life on end-stage renal disease. Health Serv Res 1989; 24 (4): 555-78
35. Nathan D. Long term complications of diabetes mellitus. N Engl J Med 1993; 328 (23): 1676-85
36. Gray A, Fenn P, McGuire A. The cost of IDDM in England and Wales. Diabet Med 1995; 12: 1068-76
37. Stern Z, Levy R. The direct cost of type I diabetes mellitus in Israel. Diabet Med 1994; 11: 528-33
38. American Diabetes Association. Direct and indirect costs of diabetes in the United States in 1992. Alexandria (VA): American Diabetes Association, 1993